DGAP-Adhoc: STADA: Dr. Axel Müller resigns his Executive Board mandate

STADA Arzneimittel AG / Key word(s): Change of Personnel

07.08.2013 11:48

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Bad Vilbel, August 7, 2013 - Dr. rer. nat. Axel Müller, Chief Production
and Development Officer, has announced his resignation from the Executive
Board of STADA Arzneimittel AG with effect from August 7, 2013 at 12:00 am.
Following the nearly complete operational implementation of the Group-wide
cost-efficiency program 'STADA - build the future', which has been ongoing
since 2010, this step is being taken for personal reasons since Dr. Müller
wants to devote himself to other tasks in the future. The resignation has
been made on the most agreeable terms with the Supervisory Board, which
released Dr. Müller from his responsibilities until the regular expiration
of his Executive Board contract on December 31, 2014. The Supervisory Board
and Executive Board wish to express their tremendous gratitude and
recognition to Dr. Müller for his many years of very successful work on
STADA's Executive Board and management.

The Supervisory Board has decided today not to fill the Executive Board
position of Production and Development for the time being. Executive Board
responsibilities for the area of Production and Development will in future
be carried out as follows: Mr. Retzlaff, Chairman of the Executive Board,
takes on additional responsibility for the areas Production, Research and
Development as well as Purchasing and Procurement. Mr. Kraft will in future
assume additional responsibility for the area Biotechnology and Dr.
Wiedenfels takes over the area Quality Assurance and Quality Control.

Additional information:
STADA Arzneimittel AG / Corporate Communications / Stadastraße 2-18 / 61118
Bad Vilbel - Germany / Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101
603-506 / E-mail: communications@stada.de
Or visit us in the Internet at www.stada.com.

---------------------------------------------------------------------------

Language: English
Company: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard);
Freiverkehr in Berlin, Hamburg, Hannover, München, Stuttgart

End of Announcement DGAP News-Service

---------------------------------------------------------------------------